2018 Round-up of Noteworthy Medicines Law and Policy Events
We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy.
January
The Chilean parliament started...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...
European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...
On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case
“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...
Cystic Fibrosis Medicines Wars in Europe
Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...
Wrapping up 2022 with some noteworthy medicines, law and policy events
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy.
Also in 2022, Covid-19 remained a central...